Co-Diagnostics – Consensus Indicates Potential 196.4% Upside

Broker Ratings

Co-Diagnostics found using ticker (CODX) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 43 and 20 with the average target price sitting at 31. With the stocks previous close at 10.46 this indicates there is a potential upside of 196.4%. There is a 50 day moving average of 10.7 and the 200 day MA is 14.57. The market cap for the company is $291m. You can visit the company’s website by visiting:

Co-Diagnostics, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index